Spelling suggestions: "subject:"tg2576"" "subject:"g2576t""
11 |
Defined astrocytic expression of human amyloid precursor protein in Tg2576 mouse brainHeiland, Tina, Zeitschel, Ulrike, Puchades, Maja A., Kuhn, Peer-Hendrik, Lichtenthaler, Stefan F., Bjaalie, Jan G., Hartlage-Rübsamen, Maike, Roßner, Steffen, Höfling, Corinna 26 September 2024 (has links)
Transgenic Tg2576 mice expressing human amyloid precursor protein (hAPP) with the Swedish mutation are among the most frequently used animal models to study the amyloid pathology related to Alzheimer's disease (AD). The transgene expression in this model is considered to be neuron-specific. Using a novel hAPP-specific antibody in combination with cell type-specific markers for double immunofluorescent labelings and laser scanning microscopy, we here report that-in addition to neurons throughout the brain-astrocytes in the corpus callosum and to a lesser extent in neocortex express hAPP. This astrocytic hAPP expression is already detectable in young Tg2576 mice before the onset of amyloid pathology and still present in aged Tg2576 mice with robust amyloid pathology in neocortex, hippocampus, and corpus callosum. Surprisingly, hAPP immunoreactivity in cortex is restricted to resting astrocytes distant from amyloid plaques but absent from reactive astrocytes in close proximity to amyloid plaques. In contrast, neither microglial cells nor oligodendrocytes of young or aged Tg2576 mice display hAPP labeling. The astrocytic expression of hAPP is substantiated by the analyses of hAPP mRNA and protein expression in primary cultures derived from Tg2576 offspring. We conclude that astrocytes, in particular in corpus callosum, may contribute to amyloid pathology in Tg2576 mice and thus mimic this aspect of AD pathology.
|
12 |
Metabolic Profiling of Suprachiasmatic Nucleus Reveals Multifaceted Effects in an Alzheimer’s Disease Mouse ModelEezaa, Muhamed N.H., Singer, Rico, Höfling, Corinna, Matysik, Jörg, de Groot, Huub J.M., Roßner, Steffen, Aliaa, A. 20 September 2024 (has links)
Background: Circadian rhythm disturbance is commonly observed in Alzheimer's disease (AD). In mammals, these rhythms are orchestrated by the superchiasmatic nucleus (SCN). Our previous study in the Tg2576 AD mouse model suggests that inflammatory responses, most likely manifested by low GABA production, may be one of the underlying perpetrators for the changes in circadian rhythmicity and sleep disturbance in AD. However, the mechanistic connections between SCN dysfunction, GABA modulation, and inflammation in AD is not fully understood.
Objective: To reveal influences of amyloid pathology in Tg2576 mouse brain on metabolism in SCN and to identify key metabolic sensors that couple SCN dysfunction with GABA modulation and inflammation.
Methods: High resolution magic angle spinning (HR-MAS) NMR in conjunction with multivariate analysis was applied for metabolic profiling in SCN of control and Tg2576 female mice. Immunohistochemical analysis was used to detect neurons, astrocytes, expression of GABA transporter 1 (GAT1) and Bmal1.
Results: Metabolic profiling revealed significant metabolic deficits in SCN of Tg2576 mice. Reductions in glucose, glutamate, GABA, and glutamine provide hints toward an impaired GABAergic glucose oxidation and neurotransmitter cycling in SCN of AD mice. In addition, decreased redox co-factor NADPH and glutathione support a redox disbalance. Immunohistochemical examinations showed low expression of the core clock protein, Bmal1, especially in activated astrocytes. Moreover, decreased expression of GAT1 in astrocytes indicates low GABA recycling in this cell type.
Conclusion: Our results suggest that redox disbalance and compromised GABA signaling are important denominators and connectors between neuroinflammation and clock dysfunction in AD.
|
13 |
β-AMYLOID, CHOLINERGIC TRANSMISSION, AND CEREBROVASCULAR SYSTEM - A DEVELOPMENTAL STUDY IN A TRANSGENIC MOUSE MODEL OF ALZHEIMER’S DISEASEKuznetsova, Elena 24 April 2013 (has links) (PDF)
Grundlage der vorgelegten Arbeit sind die bei der Alzheimerschen Erkrankung beobachtbaren pathologischen Merkmale, wie die progressive Akkumulation von β-Amyloid-Plaques, cholinerger Dysfunktion und zerebrovaskuläre Abnormalitäten. Die in englischer Sprache verfasste Dissertation ist eine tierexperimentelle Studie, die versucht, den Zusammenhang von β-Amyloid, cholinerger Neurotransmission und zerebralem Gefäßsystem bei der Alzheimerschen Erkrankung näher zu charakterisieren. An Hirnmaterial aus der transgenen Maus Tg2576, die die schwedische Mutation des humanen Amyloidpräkursorproteins als Transgen trägt und ab dem 10. Lebensmonat durch humane β-Amyloid-Plaqueablagerungen in der Hirnrinde imponiert, wurden im Altersverlauf (4 bis 18 Monate) immunhistochemische Untersuchungen zur morphologischen Integrität der zerebralen Mikrogefäße, der kortikalen cholinergen Nervterminalen und der intrazerebralen cholinergen neurovaskulären Innervation durchgeführt.
Am somatosensorischen Kortex werden beispielhaft die Expression des Glukosetransporters 1 oder Solanum tuberosum Lektin als Kapillarmarker und des vesikulären Acetylcholintransporters als Marker für cholinerge Fasern mittels Immunfluoreszenz und Laser-Scanning Mikroskopie erfasst, einer semiquantitativen Computer-gestützten Bildanalytischen Auswertung unterzogen und mit dem Ausmaß der kortikalen Plaquebeladung korreliert. So konnte gezeigt werden, dass die Dichte der Blutgefäße und cholinergen Fasern im somatosensorischen Kortex von transgenen Tieren mit dem Alter im Vergleich zu nichttransgenen Kontrolltieren abnimmt, was mit einer Reduktion der perivaskulären cholinergen Innervation einhergeht.
Die erhobenen Befunde stützen die von J.C. de la Torre und T. Mussivand schon im Jahre 1993 formulierte „vaskuläre Hypothese“, wonach bei der sporadischen Form der Alzheimerschen Erkrankung alters- und Lebensstil-bedingte Schädigungen des zerebralen Gefäßsystems eine zentrale Rolle bei der Manifestierung der Erkrankung spielen.
|
14 |
β-AMYLOID, CHOLINERGIC TRANSMISSION, AND CEREBROVASCULAR SYSTEM - A DEVELOPMENTAL STUDY IN A TRANSGENIC MOUSE MODEL OF ALZHEIMER’S DISEASEKuznetsova, Elena 24 January 2013 (has links)
Grundlage der vorgelegten Arbeit sind die bei der Alzheimerschen Erkrankung beobachtbaren pathologischen Merkmale, wie die progressive Akkumulation von β-Amyloid-Plaques, cholinerger Dysfunktion und zerebrovaskuläre Abnormalitäten. Die in englischer Sprache verfasste Dissertation ist eine tierexperimentelle Studie, die versucht, den Zusammenhang von β-Amyloid, cholinerger Neurotransmission und zerebralem Gefäßsystem bei der Alzheimerschen Erkrankung näher zu charakterisieren. An Hirnmaterial aus der transgenen Maus Tg2576, die die schwedische Mutation des humanen Amyloidpräkursorproteins als Transgen trägt und ab dem 10. Lebensmonat durch humane β-Amyloid-Plaqueablagerungen in der Hirnrinde imponiert, wurden im Altersverlauf (4 bis 18 Monate) immunhistochemische Untersuchungen zur morphologischen Integrität der zerebralen Mikrogefäße, der kortikalen cholinergen Nervterminalen und der intrazerebralen cholinergen neurovaskulären Innervation durchgeführt.
Am somatosensorischen Kortex werden beispielhaft die Expression des Glukosetransporters 1 oder Solanum tuberosum Lektin als Kapillarmarker und des vesikulären Acetylcholintransporters als Marker für cholinerge Fasern mittels Immunfluoreszenz und Laser-Scanning Mikroskopie erfasst, einer semiquantitativen Computer-gestützten Bildanalytischen Auswertung unterzogen und mit dem Ausmaß der kortikalen Plaquebeladung korreliert. So konnte gezeigt werden, dass die Dichte der Blutgefäße und cholinergen Fasern im somatosensorischen Kortex von transgenen Tieren mit dem Alter im Vergleich zu nichttransgenen Kontrolltieren abnimmt, was mit einer Reduktion der perivaskulären cholinergen Innervation einhergeht.
Die erhobenen Befunde stützen die von J.C. de la Torre und T. Mussivand schon im Jahre 1993 formulierte „vaskuläre Hypothese“, wonach bei der sporadischen Form der Alzheimerschen Erkrankung alters- und Lebensstil-bedingte Schädigungen des zerebralen Gefäßsystems eine zentrale Rolle bei der Manifestierung der Erkrankung spielen.:CHAPTER 1: INTRODUCTION
1.1 Alzheimer’s disease 1
1.2 APP processing and β-amyloid production 2
1.3 Cholinergic dysfunction in Alzheimer’s disease 5
1.4 Cerebrovascular abnormalities in Alzheimer’s disease 8
1.5 Cholinergic innervation of intracortical cerebral microvessels 9
1.6 Transgenic Tg2576 mouse model of Alzheimer’s disease 11
1.7 Aim of study 14
CHAPTER 2: MATERIALS AND METHODS
2.1 Materials 15
2.1.1 Chemical reagents used 15
2.1.2 Biological reagents used 15
2.1.3 Preparation of solutions and buffers 15
2.1.4 Antibodies and reagents used for immunohistochemistry 17
2.1.5 Transgenic animals 19
2.2 Methods 20
2.2.1 Tissue preparation and sampling of sections 20
2.2.2 Immunohistochemistry 20
2.2.2.1 Protocol of immunofluorescent labeling 20
2.2.2.2 Protocol of immunoperoxidase labeling (ABC technique) 21
2.2.2.3 Combination of primary and secondary antibodies 22
2.2.2.4 Protocol of β–amyloid immunolabeling
(Formic acid epitope retrieval method) 23
2.2.3 Histochemistry 23
2.2.3.1 Thioflavin S staining 23
2.2.3.2 Nissl staining 23
2.2.3.3 Solanum Tuberosum Lectin (STL) staining 24
2.2.4 Double and triple-coloured immuno-/ histochemical staining of brain sections 24
2.2.5 Microscopy and digital image processing 25
2.2.6 Morphological and morphometric analyses 25
2.2.6.1 Cortical microvessels 25
2.2.6.2 Cortical cholinergic innervation 27
2.2.6.2.1 Total density of VAChT-immunoreactivity 27
2.2.6.2.2 Estimation of the density of varicosities on cholinergic fibres 29
2.2.6.3 Estimation of cholinergic perivascular innervation of cortical
microvessels 29
2.2.6.4 Three-dimensional-imaging of vessels innervation 30
2.2.7 Statistical analysis 30
CHAPTER 3: RESULTS
3.1 Developmental and amyloid plaque-related changes in cerebral cortical
capillaries in transgenic Tg2576 Alzheimer mice 31
3.1.1 Morphological distribution of brain vessels in the cerebral cortex of
wild type mice 31
3.1.2 Microvessel density under plaque burden 33
3.2 Developmental and amyloid plaque-related changes in cholinergic
neurotransmission in cholinoceptive target regions of transgenic Tg2576 mice 39
3.2.1 Visualisation of cholinergic nerve terminals in mouse brain 39
3.2.2 VAChT-Expression in wild type and transgenic Tg2576 mice 40
3.3 Role of cholinergic system in β-amyloid-related changes in the cerebrovascular
system of transgenic Tg2576 mice 46
3.3.1 Solanum tuberosum lectin (STL) histochemistry in visualisation of brain
vessels, β-amyloid, and microglia 46
3.3.1.1 Solanum tuberosum lectin and brain vessels 46
3.3.1.2 Solanum tuberosum lectin and β-amyloid plaques 47
3.3.1.3 Solanum tuberosum lectin staining to visualize glial cells 48
3.3.2 Cholinergic perivascular innervation of cerebral cortical microvessels in
transgenic Tg2576 and wild type mice 50
CHAPTER 4: DISCUSSION
4.1 β-Amyloid and brain vascular system: the vascular hypothesis of Alzheimer’s disease 55
4.1.1 Evidences of a role of vascular mechanisms in Alzheimer’s disease 55
4.1.2 Effect of β-amyloid on brain vascular system 57
4.1.3 Effect of ischemia and hypoperfusion on APP processing 59
4.1.4 Effect of β-amyloid on cholinergic function in brain vascular system 59
4.2 Aim of study and main results obtained 61
4.3 Age-related changes in cerebral cortical microvessels in the presence and absence
of β-amyloid plaque load 62
4.4 Age-related changes of cholinergic terminals in cholinoceptive target regions in the presence and absence of β-amyloid plaque load 64
4.4.1 VAChT – a reliable marker for detection of cholinergic terminals
in cerebral cortex 64
4.4.2 The barrel field of the somatosensory cortex 1 (S1BF) as a model region
to reveal age-related changes in cholinergic innervation 65
4.4.3 VAChT expression: morphological and morphometric studies 66
4.5 Age-related changes in cholinergic innervation of cerebral cortical microvessels in
the presence and absence of β-amyloid plaque load 69
4.5.1 STL – a mono-marker for detection of cortical vessels, senile amyloid
plaques and activated microglia in cerebral cortex 69
4.5.2 Cholinergic perivascular innervation of cerebral cortical microvessels in
transgenic Tg2576 mice 70
4.5.3 Quantitation of cholinergic input on cerebral microvessels of mouse brain 71
4.6 Summary and conclusions 75
REFERENCES 77
|
15 |
Long-term ovarian hormone deprivation alters functionalconnectivity, brain neurochemical profile and white matter integrityin the Tg2576 amyloid mouse model of Alzheimer’s diseaseKara, Firat, Belloy, Michael E., Voncken, Rick, Sarwari, Zahra, Garima, Yadav, Anckaerts, Cynthia, Langbeen, An, Leysen, Valerie, Shah, Disha, Jacobs, Jules, Hamaide, Julie, Bols, Peter, Audekerke, Johan Van, Daans, Jasmijn, Guglielmetti, Caroline, Kantarci, Kejal, Prevot, Vincent, Roßner, Steffen, Ponsaerts, Peter, Linden, Annemie Van der, Verhoye, Marleen 12 November 2024 (has links)
Premenopausal bilateral ovariectomy is considered to be one of the risk factors of Alzheimer's disease (AD). However, the underlying mechanisms remain unclear. Here, we aimed to investigate long-term neurological consequences of ovariectomy in a rodent AD model, TG2576 (TG), and wild-type mice (WT) that underwent an ovariectomy or sham-operation, using in vivo MRI biomarkers. An increase in osmoregulation and energy metabolism biomarkers in the hypothalamus, a decrease in white matter integrity, and a decrease in the resting-state functional connectivity was observed in ovariectomized TG mice compared to sham-operated TG mice. In addition, we observed an increase in functional connectivity in ovariectomized WT mice compared to sham-operated WT mice. Furthermore, genotype (TG vs. WT) effects on imaging markers and GFAP immunoreactivity levels were observed, but there was no effect of interaction (Genotype × Surgery) on amyloid-beta-and GFAP immunoreactivity levels. Taken together, our results indicated that both genotype and ovariectomy alters imaging biomarkers associated with AD.
|
Page generated in 0.0169 seconds